Evidence map›Paper›PMID 35582638›Full record

ArticleAsian journal of pharmaceutical sciences2022

Design and fabrication of r-hirudin loaded dissolving microneedle patch for minimally invasive and long-term treatment of thromboembolic disease.

Mengfang Wu, Tian Xia, Yaran Li, Tianfa Wang, Shijia Yang, Jinchao Yu, Qiaoyan Liang, Teng Shen, Min Yu, Bing Zhao

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Recent progress on formulations of hirudin.Pharmaceutical science advances · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Mengfang WuKey Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, Shanghai 200032, China.
Tian XiaKey Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, Shanghai 200032, China.
Yaran LiKey Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, Shanghai 200032, China.
Tianfa WangKey Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, Shanghai 200032, China.
Shijia YangKey Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, Shanghai 200032, China.
Jinchao YuKey Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, Shanghai 200032, China.
Qiaoyan LiangKey Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, Shanghai 200032, China.
Teng ShenKey Laboratory of Smart Drug Delivery, Ministry of Education, Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 201203, China.
Min YuKey Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, Shanghai 200032, China.
Bing ZhaoKey Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, Shanghai 200032, China.
Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease is the leading cause of global mortality, with anticoagulant therapy being the main prevention and treatment strategy. Recombinant hirudin (r-hirudin) is a direct thrombin inhibitor that can potentially prevent thrombosis via subcutaneous (SC) and intravenous (IV) administration, but there is a risk of haemorrhage via SC and IV. Thus, microneedle (MN) provides painless and sanitary alternatives to syringes and oral administration. However, the current technological process for the micro mould is complicated and expensive. The micro mould obtained via three-dimensional (3D) printing is expected to save time and cost, as well as provide a diverse range of MNs. Therefore, we explored a method for MNs array model production based on 3D printing and translate it to micro mould that can be used for fabrication of dissolving MNs patch. The results show that r-hirudin-loaded and hyaluronic acid (HA)-based MNs can achieve transdermal drug delivery and exhibit significant potential in the prevention of thromboembolic disease without bleeding in animal models. These results indicate that based on 3D printing technology, MNs combined with r-hirudin are expected to achieve diverse customizable MNs and thus realize personalized transdermal anticoagulant delivery for minimally invasive and long-term treatment of thrombotic disease.

Indexed as

3D printing technologyAnticoagulantMicroneedle patchr-hirudin

Identifiers

PMID35582638
PMCPMC9091604
OpenAlexW4221117924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.